• 1
    Swann AC. What is bipolar disorder? Am J Psychiatry 2006;163:177179.
  • 2
    Tohen M, Calabrese JR, Sachs GS et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006;163:247256.
  • 3
    Tohen M, Zarate CA Jr, Hennen J et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry 2003;160:20992107.
  • 4
    Vieta E, Gunther O, Locklear J et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2011;14:10291049.
  • 5
    Fountoulakis KN, Kasper S, Andreassen O et al. Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 2012;262(Suppl 1):148.
  • 6
    Ketter TA, Houston JP, Adams DH et al. Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes. J Clin Psychiatry 2006;67:95101.
  • 7
    Martinez-Aran A, Vieta E, Torrent C et al. Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disord 2007;9:103113.
  • 8
    Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002;68:167181.
  • 9
    Suppes T, Vieta E, Liu S, Brescher M, Paulsson B. Maintenance treatment for patients with bipolar I disorder: results from a north American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009;166:476488.
  • 10
    Vieta E, Berk M, Wang W, Colom F, Tohen M, Baldessarini RJ. Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. J Affect Disord 2009;119:2227.
  • 11
    Calabrese JR, Vieta E, El-Mallakh R et al. Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry 2004;56:957963.
  • 12
    Colom F, Vieta E, Daban C, Pacchiarotti I, Sanchez-Moreno J. Clinical and therapeutic implications of predominant polarity in bipolar disorder. J Affect Disord 2006;93:1317.
  • 13
    Popovic D, Reinares M, Goikolea JM, Bonnin CM, Gonzalez-Pinto A, Vieta E. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol 2012;22:339346.
  • 14
    Goikolea JM, Colom F, Martinez-Aran A et al. Clinical and prognostic implications of seasonal pattern in bipolar disorder: a 10-year follow-up of 302 patients. Psychol Med 2007;37:15951599.
  • 15
    Rosa AR, Andreazza AC, Kunz M et al. Predominant polarity in bipolar disorder: diagnostic implications. J Affect Disord 2008;107:4551.
  • 16
    Vieta E. Bipolar units and programmes: are they really needed? World Psychiatry 2011;10:152.
  • 17
    Vieta E. Tertiarism in psychiatry: Barcelona Clínic Bipolar Disorders Programme. Rev Psiquiatr Salud Ment 2011;4:14.
  • 18
    Rosa AR, Reinares M, Amann B et al. Six-month functional outcome of a bipolar disorder cohort in the context of a specialized-care program. Bipolar Disord 2011;13:679686.
  • 19
    Goldberg JF, Brooks JO III, Kurita K et al. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry 2009;70:155162.
  • 20
    Tamayo JM, Zarate CA Jr, Vieta E, Vazquez G, Tohen M. Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis. Int J Neuropsychopharmacol 2010;13:813832.
  • 21
    Popovic D, Reinares M, Amann B, Salamero M, Vieta E. Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder. Psychopharmacology 2011;213:657667.
  • 22
    Keck PE Jr, Calabrese JR, McIntyre RS et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007;68:14801491.
  • 23
    Marcus R, Khan A, Rollin L et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 2011;13:133144.
  • 24
    Tohen M, Chengappa KN, Suppes T et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337345.
  • 25
    Vieta E, Montgomery S, Sulaiman AH et al. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol 2012;22:825835.
  • 26
    Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008a;109:251263.
  • 27
    Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B. Quetiapine or lithium versus placebo for maintenance treatment of bipolar I disorder after stabilization on quetiapine. Poster presented at: the 60th Institute on Psychiatric Services; October 2–5; Chicago, IL, 2008.
  • 28
    Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010;68:156162.
  • 29
    Macfadden W, Alphs L, Haskins JT et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 2009;11:827839.
  • 30
    Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010;71:130137.
  • 31
    Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60:392400.
  • 32
    Calabrese JR, Bowden CL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64:10131024.
  • 33
    Prien RF, Caffey EM Jr, Klett CJ et al. Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry 1973;28:337341.
  • 34
    Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex maintenance study group. Arch Gen Psychiatry 2000;57:481489.
  • 35
    Nivoli AM, Pacchiarotti I, Rosa AR et al. Gender differences in a cohort study of 604 bipolar patients: the role of predominant polarity. J Affect Disord 2011;133:443449.
  • 36
    Spitzer L, Williams JB, Gibson M, First MB. Clinical interview for DSM-III-R (SCID-II). Washington, DC: American Psychiatric Press, 1990.
  • 37
    Holmes TH, Rahe RH. The social readjustment rating scale. J Psychosom Res 1967;11:213218.
  • 38
    Mazzarini L, Pacchiarotti I, Colom F et al. Predominant polarity and temperament in bipolar and unipolar affective disorders. J Affect Disord 2009;119:2833.
  • 39
    Undurraga J, Baldessarini RJ, Valentí M et al. Bipolar depression: clinical correlates of receiving antidepressants. J Affect Disord 2012;139:8993.
  • 40
    Gonzalez-Pinto A, Alberich S, Barbeito S et al. Different profile of substance abuse in relation to predominant polarity in bipolar disorder: the Vitoria long-term follow-up study. J Affect Disord 2010;124:250255.
  • 41
    Baldessarini RJ, Undurraga J, Vazquez GH et al. Predominant recurrence polarity among 928 adult international bipolar I disorder patients. Acta Psychiatr Scand 2012;125:293302.
  • 42
    Bowden CL, Singh V, Weisler R et al. Lamotrigine vs. lamotrigine plus divalproex in randomized, placebo-controlled maintenance treatment for bipolar depression. Acta Psychiatr Scand 2012;126:342350.
  • 43
    Dias VV, Balanzá-Martinez V, Soeiro-De-souza MG et al. Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatr Scand 2012;126:315331.
  • 44
    Tohen M, Frank E, Bowden CL et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 2009;11:453473.
  • 45
    Colom F, Vieta E. The road to DSM-V. Bipolar disorder episode and course specifiers. Psychopathology 2009;42:209218.
  • 46
    Kessing LV, Hansen HV, Hvenegaard A et al. Treatment in a specialised out-patient mood disorder clinic v. standard out-patient treatment in the early course of bipolar disorder: randomised clinical trial. Br J Psychiatry. 2013;202:212219.